Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros












Base de dados
Intervalo de ano de publicação
1.
J Pharm Pharmacol ; 53(11): 1439-45, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11732746

RESUMO

The applicability of alpha-tocopherol as a lymphotropic carrier for a highly lipophilic drug has been evaluated. Transport to the intestinal lymph of the highly lipophilic model drug, Lu28-179, in rats after administration to the stomach in an alpha-tocopherol emulsion was compared with lymphatic transport after administration of a sesame oil emulsion and an alpha-tocopherol/sesame oil emulsion. Lymphatic transport of the triglycerides and of alpha-tocopherol was determined. A conscious rat model was used, and the mesenteric lymph was collected. There was no significant difference between the cumulative masses of triglyceride from the two emulsions containing triglyceride 24 h after administration. Administration of an alpha-tocopherol emulsion seemed to induce mobilization of endogenous triglyceride. The lymphatic transport of alpha-tocopherol was less than 1 mg 24 h after administration of both emulsions containing alpha-tocopherol. The absorption of Lu28-179 from the alpha-tocopherol emulsion was very low, with a lymphatic recovery of 0.05%. When administered in an alpha-tocopherol/sesame oil emulsion, the recovery of Lu28-179 increased sevenfold to 0.35%. However, after administration of Lu28-179 in a sesame oil emulsion, the lymphatic recovery increased a further 13-fold to 4.5%. In conclusion, the study showed that alpha-tocopherol did not promote lymphatic absorption of Lu28-179 and thus was not a good lymphotropic carrier, as compared with sesame oil. Alpha-tocopherol in combination with sesame oil was not a good lymphotropic carrier either. The non-absorbed alpha-tocopherol fraction in the intestine might be able to prevent the absorption of Lu28-179.


Assuntos
Ansiolíticos/farmacocinética , Indóis/farmacocinética , Compostos de Espiro/farmacocinética , Triglicerídeos/farmacocinética , alfa-Tocoferol/farmacocinética , Administração Oral , Animais , Ansiolíticos/química , Transporte Biológico Ativo , Indóis/química , Linfa/metabolismo , Sistema Linfático/metabolismo , Masculino , Mesentério , Modelos Animais , Ratos , Ratos Sprague-Dawley , Óleo de Gergelim/farmacologia , Compostos de Espiro/química , Triglicerídeos/metabolismo , alfa-Tocoferol/metabolismo
2.
Int J Pharm ; 222(2): 217-24, 2001 Jul 17.
Artigo em Inglês | MEDLINE | ID: mdl-11427352

RESUMO

alpha-Tocopherol is an excellent solvent for many poorly soluble drugs. The aim of this work was to study whether or not the presence of alpha-tocopherol has an influence on the solubilisation of poorly soluble drugs in simulated intestinal fluids (SIF). The solubilizing capacity of mixed micelles containing alpha-tocopherol towards three lipophilic drugs was investigated. The solubilisation of alpha-tocopherol in an aqueous micellar phase was increased by the addition of monoglycerides (MG) and free fatty acids (FFA), preferably of medium chain length, as compared to a simple bile salt solution. The addition of alpha-tocopherol to mixed micellar solutions seems to have an effect on the solubilizing capacity, which can be correlated to the partition coefficient of the drug to be solubilised. A positive effect on the solubilisation of griseofulvin and felodipine was found. For a highly lipophilic drug (Lu28-179), a positive effect on solubilisation was observed only in media containing MG and FFA of medium chain length. Generally, alpha-tocopherol cannot be considered an important factor for the solubilisation of highly lipophilic drugs in SIF. The presence of lipolytic digestion products (LDP) of the proper chain length in relation to the drug to be solubilised is much more important.


Assuntos
Química Farmacêutica , Lipídeos/química , Vitamina E/farmacologia , Antifúngicos/química , Cromatografia Líquida de Alta Pressão , Griseofulvina/química , Solubilidade/efeitos dos fármacos
3.
J Clin Periodontol ; 19(9 Pt 2): 687-92, 1992 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-1447387

RESUMO

This paper describes the development of a stable, controlled-release formulation of metronidazole for use in the treatment of periodontal disease. It is formulated as a suspension, which undergoes transformation to a release-controlling, semi-solid on contact with gingival fluid. The system is based on the ability of mixtures of monoglycerides and triglycerides to form liquid crystals, i.e., reversed hexagonals, in contact with water. The reversed hexagonal form was found to have the most favourable sustained release properties, compared with those from the cubic form. The source of metronidazole is the prodrug, metronidazole benzoate, which further helps to slow down the release rate. Product characteristics are assessed by differential scanning calorimetry and viscometry. The release data derive from the results of in vitro dissolution tests. X-ray diffraction, phase diagrams, and polarized light microscopy were used to elucidate the structure of the liquid crystalline phases.


Assuntos
Glicerídeos/química , Metronidazol/administração & dosagem , Óleo de Gergelim/química , Biodegradação Ambiental , Química Farmacêutica , Cristalização , Preparações de Ação Retardada , Difusão , Desenho de Fármacos , Implantes de Medicamento , Géis , Glicerídeos/síntese química , Humanos , Metronidazol/química , Doenças Periodontais/tratamento farmacológico , Óleo de Gergelim/síntese química , Solubilidade , Seringas , Temperatura , Viscosidade , Difração de Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...